Professional Documents
Culture Documents
REVIEW ARTICLES
Department of Anaesthesia and 2 Department of Neurology, Salford Royal Hospital, Stott Lane, Salford M6 8HD, UK
Bradford Royal Infirmary, Duckworth Lane, Bradford BD9 6RJ, UK
& The Author [2012]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
BJA
Inhalational anaesthetics
Nitrous oxide (N2O) provokes seizures in animal models
(cats), but this has not been replicated in humans. In mice,
Opioids
Meperidine is the opioid with the strongest association with
myoclonus and tonic-clonic seizure activity.24 However, fentanyl, alfentanil, sufentanil, and morphine have been
reported to cause generalized seizure patients after
low-to-moderate dose,25 26 particularly after intrathecal
use.27 29 Fentanyl and its analogues have not been shown
to possess any anticonvulsant properties.
Opioid anaesthetic agents are used to enhance EEG activity in patients with focal epilepsy. Both remifentanil and
alfentanil have been used to induce spike activity in localizing epileptogenic zones intraoperatively during epilepsy
surgery,30 although alfentanil appears to be the more
potent activator.31 The addition of alfentanil to propofol anaesthesia for electroconvulsive therapy (ECT) also increases
seizure duration.32
Table 1 Main modes of action of commonly used AEDs.6 7 *From the evidence, it is not clear which of the actions of valproate is responsible for
its actions. Lamotrigine is primarily a sodium channel blocker with some effects on T-type calcium channels
Mode of action
Antiepileptic drug
Barbiturates
Vigabatrin
Glutamate antagonist
Sodium valproate (1, 2, 3 and 4)*; lamotrigine (2 and 3)*; topiramate (1, 2, and 3)
563
BJA
myoclonus, opisthotonus, and rarely generalized seizures on
induction of anaesthesia. The highest incidence appears to
be with etomidate,36 followed by thiopental, methohexital,
and propofol. Etomidate has been shown to increase
seizure duration in ECT when compared with thiopental.37
At higher doses, all agents act as anticonvulsants.38 39
Ketamine is a non-competitive glutamate antagonist
acting at N-methyl-D-aspartate receptors, a property which
could be beneficial in management of status epilepticus refractory to other agents (see below). As with the other i.v.
agents, low doses may facilitate seizures, but at doses that
produce sedative or anaesthetic effects, ketamine shows
anticonvulsant properties.40
Benzodiazepines
Local anaesthetics
Local anaesthetic agents readily cross the blood brain
barrier, causing sedation and analgesia followed by generalized convulsions at higher doses.42 43 High blood levels result
from an accidental i.v. administration or rapid systemic absorption from a highly vascular area.44
I.V. lidocaine has been used to treat status epilepticus in
several small series, mainly in children.45 47 It was not associated with any major adverse events in these reports, but its
efficacy and role in management of status epilepticus in
adults remain to be proven.
564
Status epilepticus
Status epilepticus is a common medical emergency. The
traditional definition of status epilepticus as a seizure
lasting or recurring without regaining of consciousness over
a 30 min period is primarily useful for epidemiological purposes. In clinical practice, most convulsive seizures abate
within 2 3 min and a seizure that continues for more than
5 min has a low chance of terminating spontaneously, so
should be treated with emergency antiepileptic
medications.51
All benzodiazepines in clinical practice possess potent anticonvulsant properties.41 Diazepam, midazolam, and lorazepam are widely used to terminate episodes of status
epilepticus (see below).
Perks et al.
BJA
Generalized
convulsions
Motor
Myo
Isolated
PEDS
Lengthen
Phase II
AP normal
Glucose
pH Lactate
Phase I
AP
Lactate Glucose
Systemic
Electromechanical
dissolution
us
Seizures
Recurrent seizures
EEG
clon
Respiratory compromise
Hypothermia
Transition
Con
Brain
damage
Brain
utilization
nvu
lsive
1
CBF
Oxygen
utilization
2
3
Brain glucose
4
30
Minute
60
Time
Hour
Fig 1 Physiological changes occurring during prolonged status epilepticus. Adapted from Shorvon.106 PED, periodic epileptic discharge; CBF,
cerebral blood flow. 1, Loss of reactivity of brain oxygen tension; 2, mismatch between the sustained increase in oxygen and glucose utilization
and a decrease in cerebral blood flow; 3, a depletion of cerebral glucose and glycogen concentrations; 4, a decline in cerebral energy state.
noted that these changes occur more rapidly in CSE, but can
also occur in non-CSE (NCSE).52
565
Brain
metabolism
ive
-co
Non
Brain parenchyma
oxygenation
Glucose utilization
vuls
BJA
Perks et al.
Table 2 Drug administration details for CSE.102 Doses are i.v. unless stated otherwise
Drug
Dose
Other information
10 mg nasal or buccal
Diazepam
Diazepam
Established CSE
Phenytoin
Phenobarbital
Sodium
valproate107
Levetiracetam
Refractory CSE
100 250 mg i.v. bolus (then 50 mg increments until seizures
controlled) then 3 5 mg kg21 h21
Midazolam
0.1 0.3 mg kg21 bolus then 0.05 0.4 mg kg21 h21 infusion
Propofol
Ketamine
566
Thiopental
BJA
567
BJA
consciousness with automatisms may not always be present.
This should be considered in the differential diagnosis of all
confusional states, especially if there is a previous history
of epilepsy or a structural brain abnormality. Absence and
complex partial status are not associated with the same
extent of cerebral damage as generalized tonic-clonic seizures. The risk-associated aggressive treatment with i.v.
drugs is therefore thought not to be justifiable. Optimizing
existing AED therapy and use of oral benzodiazepines is
often sufficient to improve consciousness level. The EEG diagnosis may require administration of rapidly acting i.v. AEDs
such as diazepam during EEG recording to observe clinical
and EEG response.101
Perks et al.
Funding
None.
References
1
Conclusions
Anaesthetists encounter epilepsy commonly in the perioperative setting. They may also be involved in airway management and administration of general anaesthesia for
treatment of status epilepticus. Awareness of pharmacological properties of AEDs and potential interactions with
drugs used in anaesthesia is essential for adequate management of patients with epilepsy. While certain anaesthetic
agents can provoke seizures, recovery from anaesthesia can
be associated with shivering and myoclonus, which does
not indicate epilepsy. Patients with epilepsy may experience
breakthrough seizures in the perioperative period, but psychogenic non-epileptic attacks can also occur in this setting.
Status epilepticus is a common neurological emergency
and requires urgent management. Loss of benzodiazepine
responsiveness is a prominent feature in established CSE
and prompt treatment is important for seizure termination,
in addition to appropriate resuscitation. Second-line agents
include phenytoin or fosphenytoin and valproate, with
newer agents such as levetiracetam and lacosamide yet to
demonstrate clear evidence of efficacy. For refractory status
epilepticus, general anaesthesia with midazolam, propofol,
or thiopental is the currently accepted treatment. Opioids
should be avoided. Clinical seizures can become less prominent over time and electrographic monitoring is mandatory to
ensure that seizure control is achieved. NCSE should be considered in the unconscious patient where the cause is
unclear.
Declaration of interest
Speaker fee and conference hospitality given to R.M. from
both UCB pharma (manufacturers of levetiracetam and
568
7
8
9
10
11
12
13
14
15
16
17
Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30:
38999
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and
concepts for organization of seizures and epilepsies: report of
the ILAE Commission on Classification and Terminology,
20052009. Epilepsia 2010; 51: 676 85
Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of
effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an
unblinded randomised controlled trial. Lancet 2007; 369:
100015
Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of
effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised
controlled trial. Lancet 2007; 369: 101626
Brodie MJ. Antiepileptic drug therapy the story so far. Seizure
2010; 19: 6505
Rogawski MA, Bazil CW. New molecular targets for antiepileptic
drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep 2008; 8: 345 52
Meldrum BS, Rogawski MA. Molecular targets for antiepileptic
drug development. Neurotherapeutics 2007; 4: 18 61
Anderson J, Moor CC. Antiepileptic drugs: a guide for the nonneurologist. Clin Med 2010; 10: 54 8
Patsalos PN, Perucca E. Clinically important drug interactions in
epilepsy: interactions between antiepileptic drugs and other
drugs. Lancet Neurol 2003; 2: 47381
Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs.
Expert Rev Neurother 2010; 10: 11940
Patsalos PN, Perucca E. Clinically important drug interactions in
epilepsy: general features and interaction between antiepileptic
drugs. Lancet Neurol 2003; 2: 347 56
Haroutiunian S, Ratz Y, Rabinovich B, Adam M, Hoffman A.
Valproic acid plasma concentration decreases in a
dose-independent manner following administration of meropenem: a retrospective study. J Clin Pharmacol 2009; 49: 1363 9
Mancl EE, Gidal BE. The effect of carbapenem antibiotics on
plasma concentrations of valproic acid. Ann Pharmacother
2009; 43: 20827
Kofke WA. Anesthetic management of the patient with epilepsy
or prior seizures. Curr Opin Anesthesiol 2010; 23: 3919
Vaughn LK, Pruhs RJ. Strain-dependent variability in nitrous
oxide withdrawal seizure frequency. Life Sci 1995; 57: 112530
Artru AA, Lettich E, Colley PS, Ojemann GA. Nitrous oxide: suppression of focal epileptiform activity during inhalation, and
spreading of seizure activity following withdrawal. J Neurosurg
Anesthesiol 1990; 2: 18993
Hornbein TF, Eger EI II, Winter PM, Smith G, Weststone D,
Smith KH. The minimum alveolar concentration of nitrous
oxide in man. Anesth Analg 1982; 61: 553 6
39 Smith M, Smith SJ, Scott CA, Harkness WF. Activation of the electrocorticogram by propofol during surgery for epilepsy. Br J
Anaesth 1996; 76: 499502
40 Myslobodsky MS, Golovchinsky V, Mintz M. Ketamine: convulsant
or anti-convulsant? Pharmacol Biochem Behav 1981; 14: 27 33
41 Modica PA, Tempelhoff R, White PF. Pro- and anticonvulsant
effects of anesthetics (Part II). Anesth Analg 1990; 70: 43344
42 Usubiaga JE, Moya F, Wikinski JA, Wikinski R, Usubiaga LE. Relationship between the passage of local anaesthetics across the
bloodbrain barrier and their effects on the central nervous
system. Br J Anaesth 1967; 39: 9437
43 Steen PA, Michenfelder JD. Neurotoxicity of anesthetics.
Anesthesiology 1979; 50: 437 53
44 Veering BT. Complications and local anaesthetic toxicity in regional anaesthesia. Curr Opin Anaesthesiol 2003; 16: 4559
45 Pascual J, Ciudad J, Berciano J. Role of lidocaine (lignocaine) in
managing status epilepticus. J Neurol Neurosurg Psychiatry
1992; 55: 49 51
46 Hamano S, Sugiyama N, Yamashita S, et al. Intravenous lidocaine for status epilepticus during childhood. Dev Med Child
Neurol 2006; 48: 220 2
47 Yildiz B, Citak A, Ucsel R, Karabocuoglu M, Aydinli N, Uzel N. Lidocaine treatment in pediatric convulsive status epilepticus.
Pediatr Int 2008; 50: 359
48 Katz Y, Weizman A, Pick CG, et al. Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity. Brain Res 1994; 646: 23541
49 Lanier WL, Milde JH, Michenfelder JD. Cerebral stimulation following succinylcholine in dogs. Anesthesiology 1986; 64: 551 9
50 Schneck HJ, Rupreht J. Central anticholinergic syndrome (CAS) in
anesthesia and intensive care. Acta Anaesthesiol Belg 1989; 40:
219 28
51 Lowenstein DH, Bleck T, Macdonald RL. Its time to revise the
definition of status epilepticus. Epilepsia 1999; 40: 1202
52 Kelso ARC, Cock HR. Status epilepticus. Practical Neurol 2005; 5:
322 33
53 Kapur J, Macdonald RL. Rapid seizure-induced reduction of
benzodiazepine and Zn2+ sensitivity of hippocampal dentate
granule cell GABAA receptors. J Neurosci 1997; 17: 753240
54 Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors,
loss of inhibition, and a mechanism for pharmacoresistance in
status epilepticus. J Neurosci 2005; 25: 7724 33
55 Ashrafi MR, Khosroshahi N, Karimi P, et al. Efficacy and usability
of buccal midazolam in controlling acute prolonged convulsive
seizures in children. Eur J Paediatr Neurol 2010; 14: 4348
56 Nakken KO, Lossius MI. Buccal midazolam or rectal diazepam for
treatment of residential adult patients with serial seizures
or status epilepticus. Acta Neurol Scand 2011; 124:
99 103
57 Aylward RL. Epilepsy: a review of reports, guidelines, recommendations and models for the provision of care for patients with
epilepsy. Clin Med 2008; 8: 4338
58 Meierkord H, Poon B, Engelsen B, et al. EFNS guideline on the
management of status epilepticus in adults. Eur J Neurol 2010;
17: 348 55
59 Schmidt D, Wilensky A. Benzodiazepines. In: Engel J, Pedly T,
eds. Epilepsy: A Comprehensive Textbook, 2nd Edn. Philadelphia,
PA: Lippincott Williams & Wilkins, 2008; 153141
60 Treiman DM, Meyers PD, Walton NY, et al. A comparison of four
treatments for generalized convulsive status epilepticus. Veterans Affairs Status Cooperative Study Group. N Engl J Med
1998; 339: 7928
569
BJA
BJA
570
61 Cock HR, Schapira AH. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM
2002; 95: 225 31
62 Towne AR, DeLorenzo RJ. Use of intramuscular midazolam for
status epilepticus. J Emerg Med 1999; 17: 323 8
63 Trinka E. What is the relative value of the standard anticonvulsants: phenytoin and fosphenytoin, phenobarbital, valproate,
and levetiracetam? Epilepsia 2009; 50(Suppl. 12): 40 3
64 Stern J, Perrucca E, Browne T. Phenytoin, fosphenytoin and other
hydantoins. In: Engel J, Pedly T, eds. Epilepsy: A Comprehensive
Textbook, 2nd Edn. Philadelphia, PA: Lippincott Williams &
Wilkins, 2008; 16202
65 Crawford TO, Mitchell WG, Fishman LS, Snodgrass SR.
Very-high-dose phenobarbital for refractory status epilepticus
in children. Neurology 1988; 38: 1035 40
66 Lee WK, Liu KT, Young BW. Very-high-dose phenobarbital for
childhood refractory status epilepticus. Pediatr Neurol 2006;
34: 63 5
67 Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin
in status epilepticus: a pilot study. Neurology 2006; 67:
340 2
68 Gilad R, Izkovitz N, Dabby R, et al. Treatment of status epilepticus
and acute repetitive seizures with i.v. valproic acid vs phenytoin.
Acta Neurol Scand 2008; 118: 296300
69 Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J.
Valproate-induced hyperammonemic encephalopathy. Acta
Neurol Scand 2006; 114: 17
70 Moddel G, Bunten S, Dobis C, et al. Intravenous levetiracetam: a
new treatment alternative for refractory status epilepticus.
J Neurol Neurosurg Psychiatry 2009; 80: 68992
71 Berning S, Boesebeck F, van Baalen A, Kellinghaus C. Intravenous levetiracetam as treatment for status epilepticus. J Neurol
2009; 256: 163442
72 Gamez-Leyva G, Aristn JL, Fernandez E, Pascual J. Experience
with intravenous levetiracetam in status epilepticus: a retrospective case series. CNS Drugs 2009; 23: 983 7
73 Beyenburg S, Reuber M, Maraite N. Intravenous levetiracetam for
epileptic seizure emergencies in older people. Gerontology 2009;
55: 27 31
74 Eue S, Grumbt M, Muller M, Schulze A. Two years of experience in
the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav 2009; 15: 4679
75 Uges JW, van Huizen MD, Engelsman J, et al. Safety and
pharmacokinetics of intravenous levetiracetam infusion as
add-on in status epilepticus. Epilepsia 2009; 50: 415 21
76 Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status
epilepticus treatment: comparison of phenytoin, valproate, and
levetiracetam. Epilepsia 2011; 52: 12926
77 Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ.
The use of topiramate in refractory status epilepticus. Neurology
2003; 60: 332 4
78 Bensalem MK, Fakhoury TA. Topiramate and status epilepticus:
report of three cases. Epilepsy Behav 2003; 4: 757 60
79 Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory
status epilepticus in children. Epilepsia 2006; 47: 1070 1
80 Albers JM, Moddel G, Dittrich R, et al. Intravenous lacosamide
an effective add-on treatment of refractory status epilepticus.
Seizure 2011; 20: 428 30
81 Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ III.
The use of lacosamide in refractory status epilepticus. Neurocrit
Care 2011; 14: 34853
Perks et al.
BJA
107 Olsen KB, Tauboll E, Gjerstad L. Valproate is an effective, welltolerated drug for treatment of status epilepticus/serial
attacks in adults. Acta Neurol Scand Suppl 2007; 187:
51 4
108 Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008; 82: 219 22
109 Sheth RD, Gidal BE. Refractory status epilepticus: response to
ketamine. Neurology 1998; 51: 1765 66
571